SRS Sequential Sindilimab in Brain Metastasis of NSLSC

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

NCT05020457 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

NCT04603807 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients

NCT06883136 ·Status: ENROLLING_BY_INVITATION

Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer

NCT00663689 ·Status: UNKNOWN ·Phase: PHASE2

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

NCT05991193 ·Status: RECRUITING

A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

NCT06182761 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer

NCT03129256 ·Status: COMPLETED ·Phase: PHASE2

Keynatinib in Treated Patients With NSCLC and Brain Metastases

NCT04824079 ·Status: COMPLETED ·Phase: PHASE2

Central Nervous System(CNS) Efficacy of Dacomitinib

NCT04675008 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

NCT04519983 ·Status: UNKNOWN ·Phase: PHASE2

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

NCT05306847 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

NCT05003037 ·Status: UNKNOWN ·Phase: PHASE2

IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

NCT02556593 ·Status: TERMINATED ·Phase: PHASE2

Liposomal Irinotecan and Apatinib in ES-SCLC

NCT06749691 ·Status: RECRUITING ·Phase: PHASE2

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

NCT06657690 ·Status: RECRUITING ·Phase: PHASE2

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

NCT03083041 ·Status: COMPLETED ·Phase: PHASE2

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

NCT06078657 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

NCT06613009 ·Status: RECRUITING ·Phase: PHASE1

Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

NCT03144856 ·Status: UNKNOWN ·Phase: PHASE2

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

NCT05987644 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

NCT06688656 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT05880706 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT04547088 ·Status: UNKNOWN ·Phase: PHASE2

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

NCT06430437 ·Status: RECRUITING ·Phase: PHASE3